WuXi AppTec offers a comprehensive platform of pulmonary disease-related services.  We provide a wide panel of validated disease models, including pulmonary fibrosis, pulmonary arterial hypertension, asthma, and chronic obstructive pulmonary disease. Our experts utilize advanced technologies with fully equipped invasive and non-invasive systems, such as the pulmonary function test system.

Fragment-based drug discovery is one of the most well-developed approaches for projects starting from small, low-affinity compounds.  Powerful biophysical and structural biology tools enable the study of large numbers of fragments and are opening new possibilities in the treatment of various diseases. WuXi AppTec offers a comprehensive fragment screening platform to support hit-to-lead optimization workflows. …Read More >

The Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS function. The binding between KRAS and SOS helps facilitate the turnover of GDP-loaded KRAS (“off” state) into its GTP-loaded “on” state.  Disrupting the SOS1-KRAS complex with an SOS1 binder is a compelling strategy to help …Read More >

The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Previously viewed as undruggable, the recent FDA approval of two KRAS G12C-selective inhibitors has offered real promise to the development of anti-RAS therapies, including mutation-specific strategies. To support the discovery of novel KRAS inhibitors, WuXi AppTec offers a comprehensive …Read More >

Cereblon (CRBN) forms an E3 ligase complex together with DDB1, CUL4, and RBX1. CRBN functions as a substrate receptor of this complex, and this protein is a key target for the action of small molecules.  Targeting of CRBN can modify its substrate specificity towards non-physiological proteins, which are subsequently ubiquitinated and degraded by the proteasome. …Read More >

TP53 is the most frequently mutated tumor suppressor gene in human cancer. Mutant p53 proteins not only lose wild-type p53-dependent tumor suppressive functions, but also frequently acquire oncogenic gain-of-functions that promote tumorigenesis.  Small molecules that can either protect p53 from negative regulators or restore the functionality of mutant p53 proteins are gaining interest, and potential drugs …Read More >

WuXi Biology offers an integrated package of preclinical cancer pharmacology services for targeted oncology and immuno-oncology.  Our platform includes in vitro cell-free and cell-based assays, a comprehensive panel of in vivo tumor models, and multidisciplinary ex vivo PD analysis services. We have pioneered the development of over 1,500 PDX models across 30 cancer types, encompassing both …Read More >

As part of our neurobiology services platform, WuXi AppTec offers a comprehensive panel of advanced technologies and validated disease models to help project teams overcome the challenges in predicting the efficacy and safety of their lead candidates. We provide a full spectrum of neurological coverage, from neurodegenerative diseases and neuropsychiatric disorders to sensory and rare disorders. …Read More >

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. WuXi AppTec has built a robust TPD discovery platform, allowing for in-depth biological and biophysical characterization of monovalent (molecular glue) and bivalent (PROTAC®) molecules through the use of target …Read More >